Similar Stories to Here's Why Clovis Oncology Dropped As Much As 21.2% Today on Bing News

Shares of Clovis Oncology (NASDAQ: CLVS) fell over 21% today after AstraZeneca (NYSE: AZN) and Merck (NYSE: MRK) reported promising data for olaparib as a treatment for BRCA-mutated ovarian cancer in patients who completed chemotherapy. The excitement is over a measure called progression-free survival (PFS), or how long a patient goes without seeing cancer worsen or reappear.In a study named SOLO-1, the median PFS for patients receiving placebo was 13.8 months.

Topics:  nasdaq   clvs    astrazeneca nyse   azn    merck nyse   mrk    brca-mutated   solo-1   clovis   oncology   pfs   today   months   olaparib   shares   receiving   median   cancer   placebo   patients   
BING NEWS:
  • Cervical cancer screening rates are dropping. Here's why that's an issue.
    While cervical cancer was once one of the most deadly cancers for American women, deaths from the disease have dropped by more than 50% since the 1970s due to prevention awareness and screening. But ...
    06/14/2024 - 4:06 am | View Link
  • Oil prices, National Amusement ends Skydance talks: Market Domination
    Yeah, I just read, you know, some recent reports on other news they had made recently Julie on Friday, you know, headlines dropped development agreement ... but BioPharma is definitely not shying away ...
    06/11/2024 - 4:40 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News